NCT01317810 is a clinical trial in Overactive Bladder (OAB), sponsored by Astellas Pharma Inc.

Who is sponsoring NCT01317810?

NCT01317810 is sponsored by Astellas Pharma Inc.

What condition does NCT01317810 study?

NCT01317810 studies Overactive Bladder (OAB).

Is NCT01317810 still recruiting?

NCT01317810 is currently withdrawn. Last updated 2 September 2015.

Last reviewed 2015-09-02 · How we verify

NCT01317810

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication

Withdrawn Last updated 2 September 2015

What this trial tests

trial in Overactive Bladder (OAB). Withdrawn.

Quick facts

Lead sponsor	Astellas Pharma Inc
Status	Withdrawn
Study type	OBSERVATIONAL

Conditions studied

Overactive Bladder (OAB) — all drugs for Overactive Bladder (OAB) →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

18 and older, any sex, with Overactive Bladder (OAB). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Overactive Bladder (OAB)

Currently open trials in the same condition.

NCT07193407 — INOPASE - Performance and Safety Study of a Personalised SNM System · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT07195656 — Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) · NA · recruiting
NCT07025044 — Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrus · recruiting
NCT07371000 — Early Detection of OAB and Elimination of Negative Impact on Quality of Life · NA · recruiting

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01317810 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 2 September 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01317810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing